News - Gastro-intestinals, Licensing

Filter

Popular Filters

1 to 25 of 34 results

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan

Otsuka and Takeda to co-promote TAK-438 in the GI therapy area in Japan

29-03-2014

Japanese drugmakers Otsuka Pharmaceutical and Takeda Pharmaceutical have entered into a co-promotion…

Asia-PacificGastro-intestinalsJapanLicensingMarkets & MarketingOtsukaPharmaceuticalTAK-438Takeda Pharmaceuticalsvonoprazan

Medigene signs collaboration with Falk Pharma for RhuDex

Medigene signs collaboration with Falk Pharma for RhuDex

19-03-2014

German biotechnology company Medigene has signed an exclusive global license agreement with drugmaker…

BiotechnologyDr Falk PharmaGastro-intestinalsGermanyLicensingMedigeneNephrology and Hepatology

Ferring in up to 76 million euro deal with TxCell for IBD drug Ovasave

Ferring in up to 76 million euro deal with TxCell for IBD drug Ovasave

17-03-2014

French biotech firm TxCell SA and privately-held Switzerland-headquartered Ferring International have…

BiotechnologyFerring PharmaceuticalsFinancialGastro-intestinalsLicensingOvaSaveTxCell

Ranbaxy and EPIRUS sign licensing agreement for Infliximab biosimilar

Ranbaxy and EPIRUS sign licensing agreement for Infliximab biosimilar

09-01-2014

India's largest drugmaker Ranbaxy Laboratories (BSE: 500359) and EPIRUS Switzerland, a wholly-owned subsidiary…

Anti-Arthritics/RheumaticsBiosimilarsEPIRUS BiopharmaceuticalsGastro-intestinalsIndiainfliximabLicensingRanbaxy LaboratoriesRemicade

NovaMedica to distribute Aptalis products in Russia

06-12-2013

Russian drugmaker NovaMedica, a joint enterprise between the Russian high-technology investment fund…

Aptalis PharmaEastern EuropeGastro-intestinalsLicensingMarkets & MarketingNovaMedicaPharmaceuticalRussia

Eisai expands marketing and supply agreement for Belviq worldwide

Eisai expands marketing and supply agreement for Belviq worldwide

08-11-2013

Japanese drug major Eisai (TYO: 4523) has expanded the marketing and supply agreement between its US…

Asia-PacificBelviqEisaiGastro-intestinalsLicensingPharmaceutical

PeptiDream and Ipsen expand their peptide drug collaboration to treat endocrinologic disease

07-10-2013

PeptiDream and Ipsen have expanded the scope of their April 2013 research collaboration and license option…

Asia-PacificGastro-intestinalsIpsenLicensingPeptiDreamPharmaceutical

GlaxoSmithKline returns rights to vercirnon

19-09-2013

US drug developer ChemoCentryx (Nasdaq: CCXI) says that partner GlaxoSmithKline (LSE: GSK), the UK’s…

ChemoCentryxGastro-intestinalsGlaxoSmithKlineLicensingNorth AmericaPharmaceuticalvercirnon

Sanofi US in deal to commercialize PA8140/PA32540

04-09-2013

The US subsidiary of French drug major Sanofi (Euronext: SAN) has entered into a deal with US drugmaker…

AspirinCardio-vascularGastro-intestinalsLicensingNorth AmericaOmeprazolePharmaceuticalPozenSanofi

Nektar hedges bets on deal with AstraZeneca

12-08-2013

Along with presenting second-quarter financial results, Howard Robin, president and chief executive of…

AstraZenecaFinancialGastro-intestinalsLicensingnaloxegolNektar TherapeuticsPharmaceutical

Second Genome in deal with Janssen on microbiome drug discovery in ulcerative colitis

06-06-2013

Second Genome has entered into an agreement with Janssen Biotech, a subsidiary of US health care giant…

Gastro-intestinalsJanssenJohnson & JohnsonLicensingPharmaceuticalResearchSecond Genome

AbbVie and Alvine link up on investigational oral therapy for celiac disease

15-05-2013

US drugmaker AbbVie (NYSE: ABBV) and privately-held Alvine Pharmaceuticals, a leader in celiac disease…

AbbVieALV003Alvine PharmaceuticalsGastro-intestinalsLicensingPharmaceuticalResearch

Positive Ph IIb results for SALVAT's tarafenacin in overactive bladder

10-04-2013

Spanish drugmaker Laboratorios SALVAT and its South Koran partner Kwang Dong Pharmaceutical have released…

Gastro-intestinalsKwang Dong PharmaceuticalLaboratorios SALVATLicensingPharmaceuticalResearchtarafenacin

NPS Pharma regains rights to Revestive and Preotact from Takeda

20-03-2013

USA-based NPS Pharmaceuticals (Nasdaq: NPSP) has re-gained the full worldwide rights from partner Takeda…

Anti-Arthritics/RheumaticsGastro-intestinalsGattexLicensingNatparaNPS PharmaceuticalsPharmaceuticalPreotactRevestiveTakeda Pharmaceuticals

Phenex in up to $135 million research collaboration with Janssen

17-12-2012

Privately-held German drug discovery firm Phenex Pharmaceuticals has entered into an agreement with Janssen…

Anti-Arthritics/RheumaticsBiotechnologyGastro-intestinalsInflammatory diseasesJanssenJohnson & JohnsonLicensingPhenex PharmaceuticalsResearch

AstraZeneca gains rights to sell Ironwood's IBS drug in China

24-10-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered into an agreement with the USA's Ironwood…

Asia-PacificAstraZenecaGastro-intestinalsIronwood PharmaceuticalsLicensinglinaclotideMarkets & MarketingNexiumNorth AmericaPharmaceutical

Theravance in up to $63.5 million deal with Alfa Wassermann for velusetrag; RuiYi links with arGEN-X on MAb

05-10-2012

USA-based Theravance (Nasdaq: THRX) and Italy headquartered Alfa Wassermann have entered into an exclusive…

Alfa WassermannarGEN-XARGX-109BiotechnologyGastro-intestinalsInflammatory diseasesLicensingOncologyPharmaceuticalRuiYiTheravancevelusetrag

Almirall gains rights for IBS drug linaclotide in Mexico

10-09-2012

Spain's largest drugmaker Almirall (ALM. MC) says it has reached an agreement with USA-based Forest Laboratories…

AlmirallForest LaboratoriesGastro-intestinalsLicensinglinaclotidePharmaceuticalSouth America

AstraZeneca to get $250 million-plus from OTC Nexium deal with Pfizer

15-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) says it has entered into an agreement with Pfizer (NYSE:…

AstraZenecaFinancialGastro-intestinalsGlobalLicensingNexiumPfizerPharmaceutical

Salix and Alfa Wassermann expand rifaximin accord

10-08-2012

USA-based Salix Pharmaceuticals (Nasdaq: SLXP) and Italy's Alfa Wassermann have entered into an exclusive…

Alfa WassermannGastro-intestinalsLicensingPharmaceuticalRespiratory and PulmonaryrifaximinSalix Pharmaceuticals

Research news: dolutegravir; TD-1211; and synaptic modulators

11-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and Japanese drugmaker Shionogi (TYO: 4507) have reported…

Anti-viralsdolutegravirGalenea CorpGastro-intestinalsGlaxoSmithKlineLicensingNeurologicalPharmaceuticalRegulationResearchShionogiTD-1211TheravanceZonegran

Ferring Pharma gains rights for elobixibat from Albireo

05-07-2012

Swiss drugmaker Ferring Pharmaceuticals has entered into a licensing agreement with Albireo AB, a Sweden-based…

AlbireoBiotechnologyelobixibatFerring PharmaceuticalsGastro-intestinalsLicensingPharmaceutical

Merck & Co to continue posting sales and profits under AstraZeneca partnership

28-06-2012

US drug giant Merck & Co (NYSE: MRK) and Anglo-Swedish major AstraZeneca have amended the option agreement…

AstraZenecaFinancialGastro-intestinalsLicensingMerck & CoNexiumPharmaceuticalPrilosec

1 to 25 of 34 results

Back to top